Tolerability and effectiveness of fluoxetine in reducing anthropometric and metabolic parameters in obese women. / Tolerabilidade e eficácia da fluoxetina na redução de parâmetros antropométricos e metabólicos em mulheres obesas

AUTOR(ES)
DATA DE PUBLICAÇÃO

2006

RESUMO

Obesity is a chronic condition that has been reaching epidemic proportions worldwide. It is a risk factor for numerous medical disorders and excessive mortality. Long-term treatment, including pharmacotherapy, may be necessary for many obese patients. This study aimed to assess the tolerability and clinical effectiveness of Fluoxetine, as an adjunct therapy to a 1.500 Kcal/day diet, in reducing anthropometric and metabolic parameters in obese women. Fluoxetine (60 mg/day), was compared to placebo in 19 obese females in a 90-day trial. Fluoxetine therapy (n=9) resulted in a statistically significant greater mean reduction in weight (-9,24 vs -1,05 kg), BMI (-3,64 vs -0,45 Kg/m²) and waist circumference (-12,3 vs -2,9 cm), than placebo group (n=10). There was also an elevation of HDL-cholesterol (p<0,01) in Fluoxetine group and mean triglycerides levels was reduced (-39,5 vs +18,7 mg/dL) when compared to placebo. Side effects most commonly reported by the patients were insomnia, nausea and somnolence. We concluded that Fluoxetine may provide an effective and well tolerated possibility in reducing anthropometric and metabolic parameters, preventing the development of cardiovascular risk factors and reducing morbidity in obese women.

ASSUNTO(S)

pharmacological treatment fluoxetina anthropometric and metabolic parameters obesity tratamento farmacológico parâmetros antropométricose e metabólicos fluoxetine obesidade

ACESSO AO ARTIGO

Documentos Relacionados